Quick Answer
C4 Therapeutics, Inc. reported Earnings Per Share Diluted of $1.27 (loss) per share for the year ending 2025.
- C4 Therapeutics, Inc. showed an increase of +16.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from C4 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), C4 Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 30.2%.
- Historical annual values: Fiscal year 2025: $1.27 (loss) per share | Fiscal year 2024: $1.52 (loss) per share | Fiscal year 2023: $2.67 (loss) per share | Fiscal year 2022: $2.62 (loss) per share | Fiscal year 2021: $1.82 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: